Zhongshan Laibo Ruichen Biomedicine Co., Ltd.

Class 1 Innovative Drug for Knee Osteoarthritis Launches Phase 1b Clinical Trial in Peking Union Medical College Hospital

Now Recruiting Participants: Phase 1b Clinical Trial of RAB001d for Knee Osteoarthritis

The 2nd Meeting of the 2nd Board of Directors & 2025 Annual Shareholders' Meeting of Rabpharma Successfully Concluded

Rabpharma Successfully Recognized as a National High-tech Enterprise

Rabpharma's RAB001 Secures Additional IND Clearance, Expanding into Osteoarthritis